Clinical Core

临床核心

基本信息

  • 批准号:
    10216759
  • 负责人:
  • 金额:
    $ 56.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-07-21 至 2022-06-30
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY The Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2)-driven coronavirus disease 2019 (COVID-19) pandemic has fundamentally changed our world, country, community and families. In patients who die of COVID-19, activation of evolutionarily-conserved inflammatory cascades results in massive increases in circulating levels of inflammatory cytokines producing vascular leak, edema of multiple critical organ (lung, kidneys, heart, brain, liver, GI tract), ultimately leading to multi-organ dysfunction including acute respiratory distress syndrome (ARDS). There is lack of deep understanding regarding the risk factors for and biology of COVID-19. The pandemic has also dramatically highlighted the multiple unmet needs in the care for patients with SARS-CoV-2 infection including the lack of validated biomarkers, and of effective FDA-approved pharmacotherapies. Accordingly, this Administrative Supplement seeks to further our understanding through immunophenotyping patients who develop COVID-19. We will provide clinical data and sample collection/processing from a cohort of SARS-CoV-2 patients enrolled in Tucson, Arizona. The clinical data and samples will be transmitted to the central cores that are assigned by the Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) study with the overarching objectives to better understand the pathogenesis of COVID-19 disease and to identify immunological pathways that can be used to inform us on how to combat this disease. In Specific Aim 1, we will recruit and provide clinical data (demographics, clinical laboratory test results and imaging results, clinical course) longitudinally from patients hospitalized with COVID- 19 infection to the designated IMPACC cores in order to establish correlation with immune status and disease progression. In Specific Aim 2, we will provide biological specimens (serum, whole blood, PBMCs, nasopharyngeal samples, endotracheal aspirates) from patients hospitalized with COVID-19 infection to the designated cores in order to characterize the immunophenotypes and the immune status and response to infection. This supplement supports the University of Arizona's participation in IMPACC to facilitate screening and enrollment of inpatients with COVID-19. The proposed supplement research is within the scope of parent U19 grant entitled “Dysfunction of Innate Immunity in Asthma” (1U19AI125357). In summary, the IMPACC study coordinates a national, multi-institution consortium, collecting detailed clinical data and biologic samples from hospitalized COVID-19 infected individuals, with the goal of identifying immune signatures/molecular biomarkers associated with clinical disease course. These data will allow the prioritization of clinical interventions and therapeutic decision making.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Monica Kraft其他文献

Monica Kraft的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Monica Kraft', 18)}}的其他基金

The Duke Senescent Cell Evaluations in Normal Tissues (SCENT) Mapping Center
杜克大学正常组织衰老细胞评估 (SCENT) 绘图中心
  • 批准号:
    10689774
  • 财政年份:
    2021
  • 资助金额:
    $ 56.13万
  • 项目类别:
The Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC)
COVID-19 队列中的免疫表型评估 (IMPACC)
  • 批准号:
    10204632
  • 财政年份:
    2020
  • 资助金额:
    $ 56.13万
  • 项目类别:
University of Arizona-Banner Health All of Us Research Program
亚利桑那大学横幅健康研究计划
  • 批准号:
    10338519
  • 财政年份:
    2018
  • 资助金额:
    $ 56.13万
  • 项目类别:
Surfactant Protein-A and Type 2 Asthma in SARS-CoV-2 Infection
SARS-CoV-2 感染中的表面活性蛋白 A 和 2 型哮喘
  • 批准号:
    10661671
  • 财政年份:
    2016
  • 资助金额:
    $ 56.13万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10261953
  • 财政年份:
    2016
  • 资助金额:
    $ 56.13万
  • 项目类别:
Innate Immunity and Viral Infection in Asthma
哮喘的先天免疫和病毒感染
  • 批准号:
    10473849
  • 财政年份:
    2016
  • 资助金额:
    $ 56.13万
  • 项目类别:
Surfactant Protein-A and Type 2 Asthma in SARS-CoV-2 Infection
SARS-CoV-2 感染中的表面活性蛋白 A 和 2 型哮喘
  • 批准号:
    10261957
  • 财政年份:
    2016
  • 资助金额:
    $ 56.13万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10473850
  • 财政年份:
    2016
  • 资助金额:
    $ 56.13万
  • 项目类别:
Surfactant Protein-A and Type 2 Asthma in SARS-CoV-2 Infection
SARS-CoV-2 感染中的表面活性蛋白 A 和 2 型哮喘
  • 批准号:
    10473864
  • 财政年份:
    2016
  • 资助金额:
    $ 56.13万
  • 项目类别:
Dysfunction of Innate Immunity in Asthma
哮喘的先天免疫功能障碍
  • 批准号:
    9156365
  • 财政年份:
    2016
  • 资助金额:
    $ 56.13万
  • 项目类别:

相似海外基金

CLINICAL MODELS OF THE ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的临床模型
  • 批准号:
    6564818
  • 财政年份:
    2001
  • 资助金额:
    $ 56.13万
  • 项目类别:
ADHESION MOLECULES IN ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征中的粘附分子
  • 批准号:
    6410976
  • 财政年份:
    2000
  • 资助金额:
    $ 56.13万
  • 项目类别:
TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的治疗
  • 批准号:
    6370267
  • 财政年份:
    2000
  • 资助金额:
    $ 56.13万
  • 项目类别:
CLINICAL MODELS OF THE ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的临床模型
  • 批准号:
    6418789
  • 财政年份:
    2000
  • 资助金额:
    $ 56.13万
  • 项目类别:
TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的治疗
  • 批准号:
    6370266
  • 财政年份:
    2000
  • 资助金额:
    $ 56.13万
  • 项目类别:
TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的治疗
  • 批准号:
    6370265
  • 财政年份:
    2000
  • 资助金额:
    $ 56.13万
  • 项目类别:
CLINICAL MODELS OF THE ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的临床模型
  • 批准号:
    6302122
  • 财政年份:
    1999
  • 资助金额:
    $ 56.13万
  • 项目类别:
ADHESION MOLECULES IN ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征中的粘附分子
  • 批准号:
    6309780
  • 财政年份:
    1999
  • 资助金额:
    $ 56.13万
  • 项目类别:
CLINICAL MODELS OF THE ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征的临床模型
  • 批准号:
    6109540
  • 财政年份:
    1998
  • 资助金额:
    $ 56.13万
  • 项目类别:
ADHESION MOLECULES IN ADULT RESPIRATORY DISTRESS SYNDROME
成人呼吸窘迫综合征中的粘附分子
  • 批准号:
    6265845
  • 财政年份:
    1998
  • 资助金额:
    $ 56.13万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了